| Website | cellartis.com |
| Category | BioTech |
| Phone | 46-31-758-09-00 |
| Employees |
| TOTAL | $11.7M |
| VENTURE FUNDING TOTAL | $11.7M |
| Venture Round, 12/05 BioFund Management Innovations Kapital Catella Healthcare Investments T-bolaget | €8M |
Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine
Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
